ETHICSINTELLECTUAL PROPERTY AND ACCESS TO MEDICINES
You Are Signing the BPaL Order: Innovation's Reward or a Patient's Access?
India's Patent Office has rejected TB Alliance's patent application on the BPaL regimen for drug-resistant tuberculosis, following oppositions by patient groups. The decision clears the way for wider generic access in the country with the world's largest TB burden and revives the ethical debate between rewarding innovation and ensuring access to medicines.
UPSC Relevance9/10
Time to Read3 min read
Total Views37,635
Read Analysis